ALA - Arovella Therapeutics Limited today closed up 15% to...

ALA - Arovella Therapeutics Limited today closed up 15% to finish at 15c on $1.4m stock traded. There was no news out today but last week they announced the completion of a key manufacturing step to progress its ALA‐101 product to clinic.Arovella is developing ALA‐101 to treat CD19+ lymphomas and leukemias, it consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19 which is an antigen found on the surface of numerous cancer types.A critical component for this manufacturing is the good manufacturing practice (GMP)‐grade lentiviral vector, which carries the genetic material to program iNKT cells to target and eliminate cancer cells.The ALA‐101 vector is a 3rd generation lentiviral vector manufactured by Lentigen Technology, a world‐leading manufacturer of lentiviral vectors for cell and gene therapies.ALA's research collaborators from the Imperial College London recently presented at the 65th Annual American Society for Hematology (ASH) conference in California, you can find the presentation on the link below:https://bit.ly/47ZtuVnSome details on what they do are listed below:About Arovella Therapeutics LtdArovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours.Arovella is also expanding into solid tumour treatment through its CLDN18.2‐targeting technology licensed from Sparx Group.Additional tumour targeting technologies are anticipated to be used in conjunction with Arovella’s iNKT cell therapy platform.Arovella’s lead product is ALA‐101. ALA‐101 consists of CAR19‐iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19.CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets α‐GalCer bound CD1d, another antigen found on the surface of several cancer types.ALA‐ 101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient.